外陰膣カンジダ症薬の世界市場 2020年：メーカー別、地域別、種類・用途別

• 英文タイトル：Global Drugs for Vulvovaginal Candidiasis Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-06510 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・治療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、外陰膣カンジダ症薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。外陰膣カンジダ症薬の種類別市場規模（ミコナゾール、クロトリマゾール、フルコナゾール、エコナゾール、その他）、用途別市場規模（病院・診療所、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Bayer、Sanofi、Pfizer、Perrigo、Teva、J & J、Kingyork Group、Effik、Bristol-Myers Squibb、Cisen Pharmaceutical ・地域別グローバル市場分析 2015年-2020年 ・外陰膣カンジダ症薬の北米市場（アメリカ、カナダ、メキシコ） ・外陰膣カンジダ症薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・外陰膣カンジダ症薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・外陰膣カンジダ症薬の南米市場（ブラジル、アルゼンチン） ・外陰膣カンジダ症薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ミコナゾール、クロトリマゾール、フルコナゾール、エコナゾール、その他 ・用途別分析：病院・診療所、薬局 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The Drugs for Vulvovaginal Candidiasis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Drugs for Vulvovaginal Candidiasis sales will be xx in 2020 from Drugs for Vulvovaginal Candidiasis million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Drugs for Vulvovaginal Candidiasis market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Drugs for Vulvovaginal Candidiasis industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Drugs for Vulvovaginal Candidiasis and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Drugs for Vulvovaginal Candidiasis market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Drugs for Vulvovaginal Candidiasis market has been segmented into
Miconazole
Clotrimazole
Fluconazole
Econazole
Other

By Application, Drugs for Vulvovaginal Candidiasis has been segmented into:
Hospital & Clinic
Pharmacy

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Vulvovaginal Candidiasis market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Vulvovaginal Candidiasis markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Vulvovaginal Candidiasis market.

The report offers in-depth assessment of the growth and other aspects of the Drugs for Vulvovaginal Candidiasis market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Drugs for Vulvovaginal Candidiasis Market Share Analysis
Drugs for Vulvovaginal Candidiasis competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Vulvovaginal Candidiasis sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Vulvovaginal Candidiasis sales, revenue and market share for each player covered in this report.

The major players covered in Drugs for Vulvovaginal Candidiasis are:
Bayer
Sanofi
Pfizer
Perrigo
Teva
J & J
Kingyork Group
Effik
Bristol-Myers Squibb
Cisen Pharmaceutical

Among other players domestic and global, Drugs for Vulvovaginal Candidiasis market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales, revenue and global market share of Drugs for Vulvovaginal Candidiasis in 2018 and 2019.
Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Vulvovaginal Candidiasis Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Miconazole
1.2.3 Clotrimazole
1.2.4 Fluconazole
1.2.5 Econazole
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Vulvovaginal Candidiasis Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Overview of Global Drugs for Vulvovaginal Candidiasis Market
1.4.1 Global Drugs for Vulvovaginal Candidiasis Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
1.6 COVID-19 Outbreak: Drugs for Vulvovaginal Candidiasis Industry Impact
1.6.1 COVID-19 Potential Implications for the Drugs for Vulvovaginal Candidiasis
1.6.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Drugs for Vulvovaginal Candidiasis
1.6.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.6.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.6.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.6.2 Opportunity Analysis in Covid-19 Crisis
1.6.3 Market Risk and Restraints
1.6.4 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bayer SWOT Analysis
2.1.4 Bayer Product and Services
2.1.5 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sanofi SWOT Analysis
2.2.4 Sanofi Product and Services
2.2.5 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Perrigo
2.4.1 Perrigo Details
2.4.2 Perrigo Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Perrigo SWOT Analysis
2.4.4 Perrigo Product and Services
2.4.5 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Teva
2.5.1 Teva Details
2.5.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Teva SWOT Analysis
2.5.4 Teva Product and Services
2.5.5 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 J & J
2.6.1 J & J Details
2.6.2 J & J Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 J & J SWOT Analysis
2.6.4 J & J Product and Services
2.6.5 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Kingyork Group
2.7.1 Kingyork Group Details
2.7.2 Kingyork Group Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Kingyork Group SWOT Analysis
2.7.4 Kingyork Group Product and Services
2.7.5 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Effik
2.8.1 Effik Details
2.8.2 Effik Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Effik SWOT Analysis
2.8.4 Effik Product and Services
2.8.5 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Bristol-Myers Squibb
2.9.1 Bristol-Myers Squibb Details
2.9.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Bristol-Myers Squibb SWOT Analysis
2.9.4 Bristol-Myers Squibb Product and Services
2.9.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Cisen Pharmaceutical
2.10.1 Cisen Pharmaceutical Details
2.10.2 Cisen Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Cisen Pharmaceutical SWOT Analysis
2.10.4 Cisen Pharmaceutical Product and Services
2.10.5 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2019
3.3.2 Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Regions (2015-2020)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Regions (2015-2020)
4.2 North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
4.5 South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2015-2020)
5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2015-2020)
5.2 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
5.3 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
5.4 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2015-2020)
6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2015-2020)
6.2 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
6.3 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
6.4 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
6.5 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
6.6 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Regions (2015-2020)
7.2 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7.3 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7.4 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7.5 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
7.7 Australia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2015-2020)
8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2015-2020)
8.2 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
8.3 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
9.3 Turkey Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
9.4 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
9.5 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2015-2020)
10.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2015-2020)
10.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2015-2020)
11 Global Drugs for Vulvovaginal Candidiasis Market Segment by Application
11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
11.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2015-2020)
11.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2015-2020)
12 Market Forecast
12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2021-2025)
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2021-2025)
12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025)
12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025)
12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025)
12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025)
12.2.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025)
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2021-2025)
12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2021-2025)
12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2021-2025)
12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2021-2025)
12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2021-2025)
12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Drugs for Vulvovaginal Candidiasis Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Bayer Basic Information, Manufacturing Base and Competitors
Table 9. Bayer Drugs for Vulvovaginal Candidiasis Major Business
Table 10. Bayer Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 11. Bayer SWOT Analysis
Table 12. Bayer Drugs for Vulvovaginal Candidiasis Product and Services
Table 13. Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Sanofi Basic Information, Manufacturing Base and Competitors
Table 15. Sanofi Drugs for Vulvovaginal Candidiasis Major Business
Table 16. Sanofi Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 17. Sanofi SWOT Analysis
Table 18. Sanofi Drugs for Vulvovaginal Candidiasis Product and Services
Table 19. Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Pfizer Basic Information, Manufacturing Base and Competitors
Table 21. Pfizer Drugs for Vulvovaginal Candidiasis Major Business
Table 22. Pfizer Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 23. Pfizer SWOT Analysis
Table 24. Pfizer Drugs for Vulvovaginal Candidiasis Product and Services
Table 25. Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Perrigo Basic Information, Manufacturing Base and Competitors
Table 27. Perrigo Drugs for Vulvovaginal Candidiasis Major Business
Table 28. Perrigo Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 29. Perrigo SWOT Analysis
Table 30. Perrigo Drugs for Vulvovaginal Candidiasis Product and Services
Table 31. Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Teva Basic Information, Manufacturing Base and Competitors
Table 33. Teva Drugs for Vulvovaginal Candidiasis Major Business
Table 34. Teva Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 35. Teva SWOT Analysis
Table 36. Teva Drugs for Vulvovaginal Candidiasis Product and Services
Table 37. Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. J & J Basic Information, Manufacturing Base and Competitors
Table 39. J & J Drugs for Vulvovaginal Candidiasis Major Business
Table 40. J & J Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 41. J & J SWOT Analysis
Table 42. J & J Drugs for Vulvovaginal Candidiasis Product and Services
Table 43. J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Kingyork Group Basic Information, Manufacturing Base and Competitors
Table 45. Kingyork Group Drugs for Vulvovaginal Candidiasis Major Business
Table 46. Kingyork Group Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 47. Kingyork Group SWOT Analysis
Table 48. Kingyork Group Drugs for Vulvovaginal Candidiasis Product and Services
Table 49. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Effik Basic Information, Manufacturing Base and Competitors
Table 51. Effik Drugs for Vulvovaginal Candidiasis Major Business
Table 52. Effik Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 53. Effik SWOT Analysis
Table 54. Effik Drugs for Vulvovaginal Candidiasis Product and Services
Table 55. Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 57. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Major Business
Table 58. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 59. Bristol-Myers Squibb SWOT Analysis
Table 60. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product and Services
Table 61. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 63. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Major Business
Table 64. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Total Revenue (USD Million) (2018-2019)
Table 65. Cisen Pharmaceutical SWOT Analysis
Table 66. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product and Services
Table 67. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 68. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2018-2019) (K Units)
Table 69. Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2018-2019) (USD Million)
Table 70. Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2015-2020) (K Units)
Table 71. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2015-2020)
Table 72. Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2015-2020) (USD Million)
Table 73. North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2015-2020) (K Units)
Table 74. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2015-2020)
Table 75. North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2015-2020) (USD Million)
Table 76. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020)
Table 77. Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2015-2020) (K Units)
Table 78. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2015-2020)
Table 79. Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2015-2020) (USD Million)
Table 80. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Regions (2015-2020) (K Units)
Table 81. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2015-2020)
Table 82. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Regions (2015-2020) (USD Million)
Table 83. South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2015-2020) (K Units)
Table 84. South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2015-2020)
Table 85. South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2015-2020) (USD Million)
Table 86. South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020)
Table 87. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2015-2020) (K Units)
Table 88. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2015-2020)
Table 89. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2015-2020) (USD Million)
Table 90. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020)
Table 91. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2015-2020) (K Units)
Table 92. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2015-2020)
Table 93. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2015-2020) (USD Million)
Table 94. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2015-2020)
Table 95. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2015-2020) (K Units)
Table 96. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2015-2020)
Table 97. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Regions (2021-2025) (K Units)
Table 98. Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Regions (2021-2025)
Table 99. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2021-2025) (K Units)
Table 100. Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2021-2025)
Table 101. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2021-2025)
Table 102. Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2021-2025)
Table 103. Direct Channel Pros & Cons
Table 104. Indirect Channel Pros & Cons
Table 105. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Picture
Figure 2. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type in 2019
Figure 3. Miconazole Picture
Figure 4. Clotrimazole Picture
Figure 5. Fluconazole Picture
Figure 6. Econazole Picture
Figure 7. Other Picture
Figure 8. Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2018
Figure 9. Hospital & Clinic Picture
Figure 10. Pharmacy Picture
Figure 11. Global Drugs for Vulvovaginal Candidiasis Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2019
Figure 32. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 37. Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions (2015-2020)
Figure 39. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2018
Figure 40. North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
Figure 43. South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020)
Figure 45. North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2015-2020)
Figure 47. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2018
Figure 48. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2018
Figure 50. United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2019
Figure 56. Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 57. UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 58. France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions 2019
Figure 64. China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 67. India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 69. South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2019
Figure 71. South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2019
Figure 72. Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Turkey Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 81. South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Global Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2025) (K Units)
Figure 83. Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025) (K Units)
Figure 85. Europe Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025) (K Units)
Figure 86. Asia-Pacific Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025) (K Units)
Figure 87. South America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025) (K Units)
Figure 88. Middle East & Africa Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2021-2025) (K Units)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel

---